“Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer”
Abstract Background ROS1 fusion is an infrequent, but attractive target for therapy in patients with metastatic non- small-cell lung cancer. In studies on mainly late-stage disease, the prevalence of ROS1 fusions is about 1–3%. In early-stage lung cancer ROS1 might also provide a fruitful target for...
Main Authors: | Anne Pernille Harlem Dyrbekk, Abdirashid Ali Warsame, Pål Suhrke, Marianne Odnakk Ludahl, Joakim Oliu Moe, Inger Johanne Zwicky Eide, Marius Lund-Iversen, Odd Terje Brustugun |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-05-01
|
Series: | Diagnostic Pathology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13000-023-01357-1 |
Similar Items
-
Real-World Data on EGFR and ALK Testing and TKI Usage in Norway—A Nation-Wide Population Study
by: Inger Johanne Zwicky Eide, et al.
Published: (2023-02-01) -
Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer
by: Zeinab Kosibaty, et al.
Published: (2022-07-01) -
Comparison between Immunocytochemistry, FISH and NGS for <i>ALK</i> and <i>ROS1</i> Rearrangement Detection in Cytological Samples
by: Diane Frankel, et al.
Published: (2022-09-01) -
Novel insights into molecular patterns of ROS1 fusions in a large Chinese NSCLC cohort: a multicenter study
by: Shengyu Zhou, et al.
Published: (2023-10-01) -
Molecular characterization of genomic breakpoints of ALK rearrangements in non‐small cell lung cancer
by: Zizong Wang, et al.
Published: (2023-05-01)